Diamyd Medical
7,82
SEK
+0,26 %
Mindre end 1K følgere
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+0,26%
-4,53%
-58,57%
-51,92%
-41,53%
-24,14%
-53,01%
-56,14%
+162,04%
Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.
Læs mereMarkedsværdi
1,02 mia. SEK
Aktieomsætning
2,8 mio. SEK
Omsætning
130 t
EBIT %
-112.746,15 %
P/E
-
Udbytteafkast, %
-
Finanskalender
25.6
2025
Delårsrapport Q3'25
8.10
2025
Årsrapport '25
Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Diamyd Medical AB: Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment
Diamyd Medical AB: Diamyd Medical publishes prospectus with regards to the rights issue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools